BENAZEPRIL

Fetal Risk Summary

Benazepril is an angiotensin-converting enzyme inhibitor. No reports of the use of this agent in human pregnancy have been located, but this class of drugs should be used with caution, if at all, during gestation. Use of angiotensin converting enzyme inhibitors limited to the 1st trimester does not appear to present a significant risk to the fetus, but fetal exposure after this time has been associated with teratogenicity and severe toxicity in the fetus and newborn, including death. See Captopril or Enalapril for a summary of fetal and neonatal effects from these agents.

[*Risk Factor DM if used in 2nd or 3rd trimesters.]

Breast Feeding Summary

No reports describing the use of benazepril during lactation have been located. Because of its relatively low molecular weight (about 461), passage into milk should be expected. Other agents in this class are excreted into milk and, because the amounts are low and no adverse effects have been observed in nursing infants, are considered to be compatible with breast feeding (see also Captopril and Enalapril).